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Abstract:  Harmful algal blooms (HABs) of the toxic dinoflagellate, Karenia brevis, 
produce red tide toxins, or brevetoxins. Significant health effects associated with red tide 
toxin exposure have been reported in sea life and in humans, with brevetoxins documented 
within immune cells from many species. The objective of this research was to investigate 
potential immunotoxic effects of brevetoxins using a leukemic T cell line (Jurkat) as an in 
vitro model system. Viability, cell proliferation, and apoptosis assays were conducted 
using brevetoxin congeners PbTx-2, PbTx-3, and PbTx-6. The effects of in vitro 
brevetoxin exposure on cell viability and cellular metabolism or proliferation were 
determined using trypan blue and MTT (1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan), respectively. Using MTT, cellular metabolic activity was decreased in 
Jurkat cells exposed to 5 - 10 µg/ml PbTx-2 or PbTx-6. After 3 h, no significant effects on 
cell viability were observed with any toxin congener in concentrations up to 10 µg/ml. 
Viability decreased dramatically after 24 h in cells treated with PbTx-2 or -6. Apoptosis, as 
measured by caspase-3 activity, was significantly increased in cells exposed to PbTx-2 or 
PbTx-6. In summary, brevetoxin congeners varied in effects on Jurkat cells, with PbTx-2 
and PbTx-6 eliciting greater cellular effects compared to PbTx-3.  
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1. Introduction 
 
Harmful algal blooms (HABs) occur worldwide and have been identified as one of the key threats 
to human health [1-4]. Off the southwestern coast of Florida, blooms of the toxic dinoflagellate, 
Karenia brevis, have occurred almost annually in the Gulf of Mexico for the last twenty-five years. K. 
brevis blooms, known to the public as “red tide”, produce a suite of polyether neurotoxins, collectively 
termed brevetoxins, that result in massive fish kills, large numbers of mortalities in sea turtles and 
marine mammals, contamination of shellfish, and severe respiratory effects in humans.  
Florida red tide is known to affect human health through two routes: neurotoxic shellfish poisoning 
(NSP) and inhalation. NSP results from consumption of contaminated shellfish, but has been well 
controlled through on-going shellfish monitoring programs. Inhalation of aerosolized toxins is also a 
route for human exposure, as the toxins produced by K. brevis blooms can be incorporated into marine 
aerosol [5]. Several brevetoxin congeners are produced by K. brevis, with brevetoxin-2 (PbTx-2) and 
brevetoxin-3 (PbTx-3) the most predominant forms isolated from seawater and marine aerosols [5,6]. 
Other toxin congeners, including PbTx-1, -6, and -9 and several new brevetoxin derivatives have been 
identified in natural blooms and cultures of K. brevis [7,8]. In humans, inhalation of aerosolized toxin 
produces a dry choking cough, stinging eyes and nose, and can trigger asthma attacks and exacerbate 
chronic obstructive pulmonary disease. Field studies indicate that humans with healthy as well as 
compromised airways respond to a red tide event [9-13]. 
Recent studies have suggested that airborne brevetoxins produced by red tide may be more harmful 
than health officials previously thought, with response to Florida red tide toxins possibly extending 
beyond initial acute reactions [13-15]. In support of this hypothesis are reports of a significant increase 
(54%) in emergency room admissions due to respiratory illnesses such as bronchitis and pneumonia, 
during a time period in which there was red tide compared to a time period without significant red tide 
in the area [11,14]. Such observations may be indicative of immunosuppression resulting from chronic 
exposure to aerosolized brevetoxins, and may be particularly important among persons with 
underlying respiratory disease [11,14]. Despite these facts, our current understanding of possible 
systemic health effects associated with aerosolized brevetoxins beyond initial respiratory effects is 
limited.  
Animal models indicate that brevetoxin exposure has the potential to affect the immune system in 
many species, including manatee [16,17], cormorant [18], and rat [19-21]. Demonstrated immune 
functional impairment resulting from brevetoxin exposure includes reduced phagocytosis [19], 
decreased plaque-forming ability [19,20], and decreased lymphocyte proliferation [17]. In vitro 
brevetoxin exposure has been reported to result in DNA damage in human lymphocytes [22] and to 
affect the growth of cell lines [23,24].  
The long-term effects associated with brevetoxin exposure are unknown and evidence is 
accumulating that brevetoxins may compromise health. Characterization of cellular consequences of 
brevetoxin exposure in the immune system is critical to fully understand the impact of recurrent red 
tide events on human health. The purpose of this investigation was to further current understanding of 
the effects of brevetoxins on immune cells. Using a Jurkat cell line, cell viability, cellular metabolism, 
and apoptosis were investigated following in vitro incubation with brevetoxins. Mar. Drugs 2008, 6  293
 
2. Results and Discussion 
2.1 Effects of toxin on cell viability 
Experiments were conducted to determine effects of toxin congeners PbTx-2, -3, and -6 on cell 
viability using a Jurkat cell line as target cells. The Jurkat cell line is a transformed cell line derived 
from human T-lymphocytes and is widely used to investigate a variety of cellular effects and immune 
system responses, due to the fact that these cells have many features in common with primary human T 
lymphocytes, including T-cell receptor, ion channels, and essential signaling pathways [25-27]. The 
results presented here represent in vitro data using this cell line, and as such may not necessarily be 
directly extrapolated to human immune system effects. Nonetheless, these data are valuable in 
providing initial mechanistic data and support for conducting additional research to determine the 
relevance of these data to human health.  
 
Figure 1. Percent viability of Jurkat cells treated with PbTx-2, PbTx-3, or PbTx-6 for 24 h. 
Data are represented as percent of ethanol control viability. Cells treated with PbTx-2 or 
PbTx-6 had significantly lower viability compared to corresponding ethanol controls and 
compared with viability of cells treated with PbTx-3 at concentrations indicated by *. 
Statistical differences compared to ethanol controls were determined using a t-test at each 
toxin concentration. Comparisons in viabilities among toxin congeners were determined 
using one-way ANOVA at each concentration. N=4. 
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With short-term incubation (3 h), cell viability did not decrease in response to treatment with toxins 
in concentrations as high as 10 µg/ml, with viability greater than 94% after all treatments. Cell 
viabilities following incubation of Jurkat cells with PbTx-2, -3, or -6 in concentrations of 0 – 10 µg/ml 
for 24 h are shown in Figure 1. Viabilities of cells treated with PbTx-2 or PbTx-6, but not with PbTx-Mar. Drugs 2008, 6  294
 
3, were significantly lower (P < 0.05) than ethanol controls at toxin concentrations of 1.25 µg per ml 
or greater. Viabilities of cells treated with either PbTx-2 or -6 were also significantly reduced 
compared to viability of cells treated with PbTx-3 at concentrations of 1.25 µg/ml or greater. Viability 
of cells treated with PbTx-3 was above 95% of ethanol control at all concentrations after 24 h. 
Statistical differences compared to ethanol controls were determined using a t-test at each toxin 
concentration. Comparisons in viabilities among toxin congeners were determined using one-way 
ANOVA at each concentration. After 48 h, viability was extremely low in cells treated with PbTx-2 or 
-6, with viabilities less than 30% in response to all toxin concentrations. Of interest is the observation 
that Jurkat cells treated with PbTx-3 maintained viabilities greater than 95% of ethanol control over 
the 48 h incubation period at all toxin concentrations. Viabilities of ethanol control cells over the 48 h 
incubation period did not differ from cells treated with media only and were greater than 95% after 24 
h and greater than 92% after 48 h.  
2.2 Effects of brevetoxins on cellular metabolism measured using MTT 
 The metabolic activity of brevetoxin-treated Jurkat cells was used as an indication of cell 
proliferation and was measured using MTT. Effects of brevetoxins on cellular metabolic activity in 
Jurkat cells after 1 - 3 h are shown in Figure 2 and are reported as percentage of ethanol control. 
Treatment of Jurkat cells with PbTx-2 or -6 resulted in greater effects on cell metabolic activity with 
increasing toxin concentration and exposure time. After 1, 2, and 3 h incubations, PbTx-2 and PbTx-6 
significantly (P < 0.05) decreased cellular metabolic activity at concentrations of 5 and 10 µg/ml. After 
3 h brevetoxin treatment, metabolic activity observed in response to 5 and 10 µg/ml PbTx-2 was 64 
and 47% of ethanol control, respectively. In response to treatment with PbTx-6, metabolic activity was 
80% and 60% of ethanol control in response to treatment with 5 and 10 µg/ml, respectively. During 
these time periods, PbTx-3 did not significantly affect cellular metabolism. Cells treated with PbTx-2 
or PbTx-6 had significantly lower metabolic activity compared to cells treated with PbTx-3 at 10 
µg/ml after 1, 2, and 3 h incubations and at 5 µg/ml after 2 and 3 h incubations.  
Cell metabolic activity in cells treated with brevetoxins for 24 or 48 h is shown in Figure 3. Control 
cellular metabolic activity following exposure to PbTx-2 and PbTx-6 were significantly decreased (P < 
0.05) compared to ethanol control at concentrations of 2.5 µg/ml or greater after both 24 and 48 h 
incubation periods. At toxin (PbTx-2 and PbTx-6) concentrations of 1.25 µg/ml, cells demonstrated 
approximately 50% of ethanol control metabolic activity after 24 h, but this decrease was not 
statistically significant. At concentrations of 2.5 µg/ml or greater, cells treated with PbTx-2 or PbTx-6 
had significantly less cellular metabolic activity compared with cells treated with PbTx-3 at each 
concentration. Cells treated with PbTx-3 demonstrated significantly (P < 0.05) reduced metabolic 
activity compared to ethanol control in response to 10 µg/ml toxin, but not at lower toxin 
concentrations, after both 24 and 48 h incubations, with responses approximately 70-75% that of 
ethanol controls at the same concentration.  
 Mar. Drugs 2008, 6  295
 
Figure 2. Effect of PbTx-2, PbTx-3, and PbTx-6 on cell metabolic activity in Jurkat cells 
exposed to 0 – 10 µg/ml toxin for 1, 2, or 3 h. Cellular metabolic activity was measured 
using MTT and reported as percentage of ethanol control. Cells treated with PbTx-2 and -6 
had significantly lower metabolic activity compared with corresponding ethanol controls at 
5 and 10 µg/ml, as indicated by the *. Cells treated with PbTx-2 or PbTx-6 had 
significantly lower metabolic activity compared to cells treated with PbTx-3 at 5 and 10 
µg/ml, as indicated by the +. *Significantly less (P < 0.05) than ethanol control. 
+Significantly less (P < 0.05) than treatment with PbTx-3. Changes in cellular metabolic 
activity were compared to ethanol control for each toxin congener at each concentration 
using a t-test. Changes in cellular metabolic activity in cells treated with different toxin 
congeners were determined using one-way ANOVA at each toxin concentration. N=4. 
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Figure 3. Effect of PbTx-2, PbTx-3, and PbTx-6 on cell metabolic activity in Jurkat cells 
exposed to 0 - 10 µg/ml toxin for 24 or 48 h. Cellular metabolic activity was measured 
using MTT and reported as a percentage of ethanol control. Cells treated with brevetoxins 
had significantly lower metabolic activity compared with corresponding ethanol controls at 
concentrations indicated by *. Cells treated with PbTx-2 or PbTx-6 had significantly less 
metabolic activity compared to cells treated with PbTx-3 at concentrations indicated by +. 
*Significantly less (P < 0.05) than ethanol control. +Significantly less (P < 0.05) than 
treatment with PbTx-3. Changes in cellular metabolic activity were compared to ethanol 
control for each toxin congener at each concentration using a t-test. Changes in cellular 
metabolic activity in cells treated with different toxin congeners were determined using 
one-way ANOVA at each toxin concentration. N=3. 
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2.3 Effects of in vitro brevetoxin exposure on apoptosis in Jurkat cells 
The effects of exposure to PbTx-2, PbTx-3, and PbTx-6 on apoptosis induction were determined by 
caspase-3 activity using a fluorescent microplate assay (Figure 4). Caspase-3 activity was measured 
after 3 h in response to treatment with 0-10 µg/ml toxin concentrations. Using a t-test to compare 
apoptotic activity in toxin treated cells with apoptotic activity in cells treated with ethanol control, cells 
treated with PbTx-2 or PbTx-6 were found to have significantly greater (P < 0.05) caspase-3 activity 
compared to ethanol control after 3 h exposure at concentrations of 5 and10 µg/ml, but not at 2.5 
µg/ml, with caspase activity increasing from 3- to 8-fold, depending on toxin concentration. Caspase-3 Mar. Drugs 2008, 6  297
 
activity induced by PbTx-2 was also significantly greater (P < 0.05) than that induced by PbTx-3 at 5 
and 10 µg/ml concentrations. Although treatment with PbTx-6 increased caspase-3 activity compared 
to treatment with PbTx-3 approximately 2- or 5-fold in response to 5 and 10 µg/ml, respectively, these 
differences were not statistically significant.  
Jurkat cells exposed to brevetoxins in vitro were also treated with the caspase-3 inhibitor, Ac-
DEVD-CHO. As shown in Figure 5, activation of caspase-3 in brevetoxin-exposed cells was reduced 
greater than 100-fold by treatment with this inhibitor. The results presented in Figure 5 represent an 
average of two experiments, therefore, no statistical analyses were conducted on these data.  
 
Figure 4. Caspase-3 activity in Jurkat cells incubated with 0 - 10 µg/ml PbTx-2, PbTx-3, 
or PbTx-6 for 3 h. St = Staurosporine; EtOH = ethanol control. N =5. Cells treated with 
PbTx-2 or PbTx-6 had significantly greater (P < 0.05) caspase-3 activity compared with 
corresponding ethanol controls at the concentrations indicated by *, as determined using a 
t-test at each concentration. Cells treated with PbTx-2 had significantly greater (P < 0.05) 
caspase-3 activity compared to cells treated with PbTx-3 at concentrations indicated by +, 
as determined using a one-way ANOVA at each concentration.  
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Although several studies have led to the suggestion that respiratory effects associated with red tide 
toxin exposure may not represent the full impact of brevetoxins on human health, the effects of 
brevetoxins at the cellular level are not well understood, particularly in immune cells. The objective of 
the present study was to contribute to current understanding of potential effects of brevetoxin exposure 
on immune cells using in vitro treatments of a human leukemic T cell line, Jurkat cells, which have 
been widely used to approximate various cellular effects.  
Although useful, it is difficult to make assumptions about cellular effects about environmental 
exposure based on studies with transformed cell lines such as the one used here. Although it is unlikely 
that results similar to the in vitro data presented here will be observed in immune cells following 
environmental exposure in humans, in vitro investigations such as these do play an important role in Mar. Drugs 2008, 6  298
 
understanding human health risk assessment by providing initial mechanistic data [28], albeit without 
the pathways of absorption, distribution, and excretion that would be involved following 
environmental exposure. Although in vitro data with a transformed cell line cannot be directly 
extrapolated to human health risks, these provide valuable information to help direct future 
investigations of environmental exposure to brevetoxins in humans.  
 
Figure 5. Effect of the caspase-3 inhibitor, Ac-DEVD-CHO, on caspase-3 activity in 
Jurkat cells exposed to 10 µg/ml PbTx-2 or PbTx-6 for 3 h without inhibitor (No Inh) or 
with 20 µM of Ac-DEVD-CHO (Inh). The data presented are an average of two trials of 
the experiment.  
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Brevetoxins remain in blood for several hours to days post-exposure [29-31] and become widely 
distributed throughout tissues [19,32]. Blood lipoproteins bind brevetoxins [33,34], which increases 
systemic distribution as well as the ability of toxin to enter cells. Placental transport of PbTx-3 also 
occurs [35]. These observations lend support to the hypothesis that brevetoxin exposure has the 
capacity to impact the immune system in that blood is continuously in contact with tissues and is host 
to effector immune cells. 
Several potential mechanisms of action on immune system components have been suggested, 
including inhibition of cathepsin active sites [36,37], induction of apoptosis [16,22], and release of 
inflammatory mediators [16]. Effects on the cell cycle have also been hypothesized, based on reports 
of reduced lymphocyte proliferation in manatees [17], aberrant cell division in a cell line (SP2/0) 
exposed to brevetoxin in vitro [23], and inhibition of cellular proliferation of CHO-K1-BH4 cells [24]. 
In this paper, we address effects on brevetoxin on cellular metabolic activity and apoptosis. 
Previously published reports on effects of brevetoxin on cell proliferation have included use of a 
reagent based on mitochondrial dehydrogenase activity, WST-1 [23], and determination of cell number 
[24]. MTT, a measure of metabolic activity, specifically mitochondrial function, of viable cells, has Mar. Drugs 2008, 6  299
 
been used as a measure of cell proliferation [38-40] in other systems. Since proliferating cells are 
metabolically more active than non-proliferating cells, these assays have been considered suitable for 
measuring cell activation and proliferation [38]. In the present study, we report results on effects of 
brevetoxins using MTT as an indicator of metabolic activity, or proliferation, in a cell line. Jurkat cells 
treated with brevetoxin demonstrated significantly lower cellular metabolic activity, compared to 
control cells. Depending on toxin congener used, concentrations as low as 2.5 µg/ml significantly 
decreased this response compared to control. Han et al [23] reported a transient increase in cellular 
activity after 1.5 h exposure to brevetoxin, an effect which was not observed in the present study. Han 
et al used crude toxin extract at low concentrations, which may account for the observed differences. 
Using an increase in cell number as a measure, Sayer et al [24] reported decreased cell proliferation 
after 48 h treatment in response to toxin concentrations as low as 10
-12 M. Different cell types were 
used in both of these studies, and it is highly likely that cell types may vary in their responses to 
brevetoxin treatment. Of interest is the observation that treatment with PbTx-3 did not significantly 
decrease cellular activity or viability until a high toxin concentration (10 µg/ml). These results indicate 
that the brevetoxin congener, PbTx-3, is considerably less cytotoxic towards Jurkat cells than are 
congeners PbTx-2 or -6.  
Although many methods can be used to detect apoptosis, activation of caspase-3 is among the more 
commonly used. In the present study, caspase-3 activity was used to measure apoptosis in Jurkat cells 
exposed to brevetoxins in vitro, with a significant increase in apoptotic signaling events in response to 
PbTx-2 and -6, but not PbTx-3, observed. Although high concentrations of toxin were required to elicit 
activation of caspase-3, these data suggest that PbTx-3 and -6 have the ability to induce apoptosis, 
observations which are consistent with DNA damage reported by Sayer et al [22] and activation of 
interleukin-1-converting enzyme observed in manatees [16]. Sayer et al [22] reported DNA damage 
occurring in response to much lower brevetoxin concentrations, approximately 800 nM, with no 
differences among toxins.  
Apoptosis primarily occurs through two defined pathways: the death receptor, or extrinsic, and the 
mitochondrial, or intrinsic, pathways. The extrinsic pathway, initiated by a family of cell surface death 
receptors, generates an apoptotic signal which may not involve mitochondria. The intrinsic pathway, 
on the other hand, is triggered by various signals which lead to disruption of mitochondrial function 
and activation of caspases, including caspase-3. Activation of caspases is responsible for events 
leading to morphological changes associated with apoptosis, such as DNA degradation, chromatin 
condensation, and membrane blebbing. The intrinsic pathway is regulated by the Bcl-2 family of 
proteins which includes Bax/Bak as integral components. The intrinsic pathway of apoptosis also 
involves disruption of mitochondrial function by affecting the transmembrane potential across the 
mitochondrial membrane and leading to the release of cytochrome c. The results reported here in 
which a decrease in cell metabolic activity, i.e., mitochondrial function, was demonstrated in immune 
cells exposed to brevetoxins in vitro, lends support to the hypothesis that brevetoxins may induce 
apoptosis through the intrinsic pathway. Based on activation of caspase-3 by brevetoxins, reports of 
DNA damage, and elimination of caspase-3 activity using the inhibitor Ac-DEVD-CHO, it is likely 
that brevetoxin-induced apoptosis proceeds through the intrinsic pathway and involves critical 
mediators such as Bax/Bak. Although apoptosis does occur in response to brevetoxin treatment, due to Mar. Drugs 2008, 6  300
 
the high toxin concentrations required, the results of the present study do not support the hypothesis 
that apoptosis is a primary mechanism of toxin effect in an immune-derived transformed cell line.  
The data presented here consistently indicate that PbTx-3 exerts fewer effects on Jurkat cells 
compared with PbTx-2 or -6. Reports of effects of different toxin congeners vary, with some studies 
reporting no measurable differences in cellular effects elicited by toxin congeners either in vitro [22] or 
in vivo [41], whereas other studies do report congener-dependent effects [24,29]. Specifically, Radwan 
et al [29] report different processing of PbTx-2 and -3 in an animal model. Some differences in cellular 
effects elicited toxin congeners may be attributed to specific receptors, cellular metabolism, or 
biotransformation enzymes in target cells. Certain structural features among brevetoxins contribute to 
varying potencies and mechanisms of action [38-40]. For example, due to the very reactive α,β-
unsaturated aldehyde group of PbTx-2, this congener is more reactive toward glutathione compared to 
PbTx-3, and is rapidly metabolized and excreted [29]. PbTx-6, but not -2 or -3, binds the aryl 
hydrocarbon receptor [45]. PbTx-6 is an epoxide metabolite and readily binds cellular molecules, 
which has the potential to lead to genotoxic effects [46].  
Brevetoxins have been shown to undergo cellular metabolism through known xenobiotic 
biotransformation pathways for detoxification, primarily in the liver [25,45-47]. Although liver is 
considered the primary site for xenobiotic transformation, many of these enzymes are also present in 
peripheral blood lymphocytes and function in toxin metabolism [48-50]. The presence of these 
enzymes in immune cells may contribute to some of the variation in cytotoxic effects of toxin 
congeners observed in the research presented here. Brevetoxin metabolites generated by 
biotransformation pathways in immune cells may result in potentially significant and long-lasting 
impacts on the immune system. 
Karenia brevis red tide blooms along the Florida Gulf Coast generally result in brevetoxin 
concentrations in seawater from 5 – 30 µg/L, depending on many factors, including cell count and age 
of the bloom [5], with variations in the toxin congener composition of each bloom. The experiments 
conducted in this study utilized brevetoxin concentrations that were much higher than environmental 
exposure, an approach not uncommon for initial toxicology studies, in order to direct future research 
geared towards understanding effects of environmental exposures. In that regard, high toxin 
concentrations were utilized in short-term in vitro experiments to facilitate detection of cellular events 
potentially impacted by brevetoxin exposure. Although toxin concentrations used in these in vitro 
studies are not likely to be encountered in the environment in a single exposure event, circulation and 
bioaccumulation of toxins may result in substantially increased toxin load over repeat exposures.  
The objective of this study was to determine how brevetoxins, naturally produced in the marine 
environment, may potentially affect cells of immune origin. Harmful effects of brevetoxins on the 
health of sealife have been well-documented [16-18]. Effects on human health, beyond respiratory 
irritation, are essentially unknown, with immunotoxic effects of brevetoxins only in the initial phases 
of investigation. The range of K. brevis blooms is extending [1], potentially impacting a greater 
percentage of the population. Also of concern is the fact that brevetoxins can become aerosolized and 
carried greater than a mile inland, thus increasing the range of potential brevetoxin exposure beyond 
the immediate coastline (Kirkpatrick et al., pers comm.). Although exposure to harmful algal blooms is 
a significant health concern, few reports have been published regarding immune system effects 
associated with brevetoxin exposure. To improve our understanding of potential effects of red tide Mar. Drugs 2008, 6  301
 
toxin on the immune system, in vitro experiments using a leukemic T cell line, Jurkat, were conducted. 
The results presented here suggest brevetoxin exposure may elicit important cellular effects, including 
apoptosis, cell metabolism and proliferation, and cytotoxicity, in an immune-derived transformed cell 
line following in vitro exposure. These observations support the hypothesis that brevetoxin exposure 
may affect cellular functions and consequently, may have the potential to impact immune function, 
although additional studies are required to determine the relevance of these data to human health. Of 
interest is the fact that one of the major toxin congeners detected in marine aerosols [6], PbTx-3, 
demonstrated only minimal effects on immune cells, although these effects became enhanced with 
increasing time of exposure and concentration. On the other hand, PbTx-2, another major toxin 
congener in K. brevis blooms [6], appears to disrupt cellular metabolism and induce apoptosis in 
immune cell targets in this in vitro cell culture system. PbTx-6, a minor and infrequent component of 
blooms [6] and a biotransformation product of PbTx-2 [46], elicits cellular effects similar to those 
observed with PbTx-2. The data presented here generate additional questions regarding effects of 
brevetoxins on immune cells at the cellular level and indicate that such effects warrant further in-depth 
investigations into mechanisms of action of brevetoxins on immune cells. Exposure to aerosolized 
harmful algal blooms may be a significant health concern and characterization of effects of red tide 
toxins on immune health is essential. In vitro experiments such as these provide direction for future 
research efforts to more fully understand the pathogenesis of brevetoxin exposure at the cellular level 
and help delineate potential harmful effects of brevetoxins on immune function. 
3. Experimental Section 
3.1 Cells 
The human leukemic T cell line, Jurkat clone E-6, was obtained from the American Type Culture 
Collection (Manassas, VA). Cells were cultured in RPMI 1640, pH 7.4, containing 10% heat-
inactivated fetal bovine serum (FBS; Hyclone, Logan UT), 100 units/ml penicillin-streptomycin 
(Sigma Chemical Co., St. Louis, MO), and 100 µg/ml amphotericin B (Sigma). Cells were cultured in 
a humidified 5% CO2 atmosphere at 37 ºC and media renewed every 2-3 days as recommended.  
3.2 Toxins 
Brevetoxin congeners PbTx-2, PbTx-3, and PbTx-6 were obtained from Dr. Dan Baden, University 
of North Carolina, Wilmington, NC. Individual neat toxin standards were reconstituted at a 
concentration of 500 µg/ml in a solution of 80% ethanol in HPLC water. To confirm purity and toxin 
concentration, brevetoxin analyses were performed by liquid chromatography mass spectrometry 
(LC/MS) using a ThermoFinnigan AqA LC/MS (Thermo Electron Corp, Madison, WI) single quad 
system scanned from 204-1216 AMU according to the procedures of Pierce et al. [51]. The column 
was a Phenomenex Luna C-18 reverse-phase 5 µ particle size, 250 mm x 2 mm analytical column with 
solvent gradient of acidified (0.3% acetic acid) acetonitrile (ACN/H2O) with initial 50:50 ACN/H2O 
over 40 min. The instrument was calibrated with a standard brevetoxin mixture containing PbTx-2 and 
PbTx-3. The toxin concentrations used in cell cultures ranged from 0.15 – 10 µg/ml (0.17 – 11 µM) 
final concentration. For each toxin concentration, an ethanol control was prepared from 80% ethanol in 
HPLC water used to reconstitute neat toxins.  Mar. Drugs 2008, 6  302
 
3.3 Cell Viability 
Effects of toxin exposure on cell viability were determined using trypan blue exclusion [50]. Cells 
were adjusted to a concentration of 2 x 10
6 cells/ml, distributed into wells of a 96-well plate, and 
synchronized by overnight serum starvation. Plates were centrifuged at 300 x g for 7 min, the 
supernatant removed, and 100 µl cell culture medium (RPMI 1640 containing 10% FBS) and the 
appropriate concentration (0 – 10 µg/ml) of PbTx-2, PbTx-3, or PbTx-6 was added. After 3, 24, or 48 
h incubation periods, the cells were diluted 1:1 with trypan blue and counted using a hemacytometer. 
The percentage of live cells in each treatment was determined. Statistical differences in cell viabilities 
were determined by comparing raw data for cell viabilities at each toxin concentration with the 
corresponding ethanol control using Student’s t-test, with P < 0.05 considered significant. Statistical 
differences in viabilities among toxin congeners were determined using a one-way ANOVA at each 
toxin concentration. 
3.4 MTT Assay 
For this study, metabolic activity of viable Jurkat cells was used as a measure of cell proliferation. 
Cellular metabolic activity was measured using an MTT (1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan) assay which is now widely used to quantitate cellular proliferation and cytotoxicity 
[38,53]. Since proliferating cells are metabolically more active than non-proliferating or resting cells, 
such tetrazolium salt-based assays are frequently used to measure cell activation and proliferation.  
To synchronize the cells, Jurkat cells were incubated in serum-free medium overnight at 37 ºC in a 
5% CO2 humidified atmosphere. Experiments were done in quadruplicate using separate cell cultures. 
After 24 h, cells were centrifuged, supernatant carefully removed and cells resuspended in cell culture 
medium (RPMI 1640 containing 10% FBS) containing brevetoxins in concentrations ranging from 0 - 
10 µg/ml. Cultures were incubated for 1, 2, 3, 24, or 48 h time periods. Ethanol controls were included 
in all experiments. After the incubation period, 25 µl MTT from a 5 mg/ml stock solution prepared in 
PBS was added to each well. Plates were returned to the incubator for 4 h. After the 4 h incubation 
period, 100 µl of a solubilizing solution (0.1 N HCl, 10% SDS) was added and the plates incubated 
overnight at 37 ºC. MTT conversion was measured using a microplate reader (BioTek ELx800) with 
absorbance read at 570 nm and background absorbance at 630 nm subtracted. Cell proliferation or 
metabolism was expressed as percentage of ethanol control cells. Statistical analyses were conducted 
on raw data to compare cellular metabolic activity in brevetoxin-treated cells compared to ethanol 
control cells, with a t-test conducted with data from each individual toxin congener at each 
concentration compared to the corresponding ethanol control. Significant differences among toxin 
congeners at each concentration were examined using a one-way ANOVA to compare cellular 
metabolic activity among cells treated with PbTx-2, PbTx-3, or PbTx-6.  
3.5 Caspase-3 activity 
Apoptosis occurring in response to treatment with brevetoxin was measured using a caspase-3 
fluorescent microplate assay (Molecular Probes, Eugene, OR). Jurkat cells were adjusted to a 
concentration of 2 x 10
6 cells/ml and distributed in 100 µl volumes into wells of a 96-well microtiter 
plate and incubated with 0 – 10 µg/ml PbTx-2, PbTx-3, or PbTx-6. Staurosporine (2 µM) was used as Mar. Drugs 2008, 6  303
 
a positive control. After 3 h incubation at 37 ºC, 5% CO2, cells were pelleted by centrifugation at 600 x 
g for 5 min and washed once with PBS. Cells were resuspended in 50 µl lysis buffer (20 mM Tris, pH 
7.5, 0.2 M NaCl, 2 mM EDTA, 0.02% Triton X-100), lysed by incubating on ice for 30 min, and 
pelleted to remove debris. Supernatant was transferred from each sample to wells of a black 
microplate. Substrate (Z-DEVD-R110) was added with reaction buffer (10 mM PIPES, pH 7.4, 2 mM 
EDTA, 0.1% CHAPS) and incubated at room temperature in the dark for 30 min. In some wells, 20 
µM Ac-DEVD-CHO, a potent inhibitor of caspase-3 [55], was added 10 min before adding substrate. 
Fluorescence was measured using a microplate reader (BioTek FLx800) with excitation at 496 nm and 
emission at 520 nm. Statistical comparisons were made between toxin treated cells and ethanol control 
at each concentration using a t-test. Statistical comparisons were also made among toxin congeners at 
each concentration using one-way ANOVA.  
3.6 Statistical techniques  
Statistical analyses were conducted using SigmaStat Version 3.11. Statistical comparisons were 
made using either the Student’s t-test or one way analysis of variance (ANOVA). Tests conducted for 
each experiment are listed in the section describing that experiment and in the figure legends. P values 
less than 0.05 were considered significant. Where included, data points and error bars on the figures 
represent mean ± standard error of the mean (SEM) responses.  
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